Enhabit, Inc. (EHAB)
Largest Insider Buys in Sector
EHAB Stock Price History Chart
EHAB Stock Performance
About Enhabit, Inc.
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific …
Insider Activity of Enhabit, Inc.
Over the last 12 months, insiders at Enhabit, Inc. have bought $359,577 and sold $5,586 worth of Enhabit, Inc. stock.
On average, over the past 5 years, insiders at Enhabit, Inc. have bought $616,837 and sold $5,586 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bolton Jeffrey (director) — $341,577. Hoeflinger Erin (director) — $18,000.
The last purchase of 3,000 shares for transaction amount of $22,800 was made by Bolton Jeffrey (director) on 2024‑11‑12.
List of Insider Buy and Sell Transactions, Enhabit, Inc.
| 2024-11-12 | director | 3,000 0.006% | $7.60 | $22,800 | -1.97% | |||
| 2024-11-08 | director | 7,000 0.0139% | $7.77 | $54,377 | -3.55% | |||
| 2024-08-22 | director | 5,000 0.0099% | $8.01 | $40,050 | -4.99% | |||
| 2024-08-09 | director | 5,000 0.0098% | $8.29 | $41,450 | -6.74% | |||
| 2024-08-08 | director | 2,000 0.004% | $8.60 | $17,200 | -7.39% | |||
| 2024-05-17 | director | 10,000 0.0193% | $8.33 | $83,300 | -0.18% | |||
| 2024-05-14 | director | 2,000 0.004% | $9.00 | $18,000 | -8.95% | |||
| 2024-05-10 | director | 10,000 0.0197% | $8.24 | $82,400 | -0.72% | |||
| 2024-03-01 | Sale | EVP Clinical Excel. & Strategy | 634 0.0013% | $8.81 | $5,586 | +0.57% | ||
| 2023-05-26 | director | 2,000 0.004% | $11.61 | $23,220 | -7.53% | |||
| 2023-05-22 | director | 10,000 0.0198% | $11.98 | $119,800 | -12.08% | |||
| 2023-05-18 | EVP Clinical Excel. & Strategy | 10,000 0.02% | $11.99 | $119,900 | -10.68% | |||
| 2023-05-18 | director | 2,100 0.0042% | $11.82 | $24,822 | -10.68% | |||
| 2023-05-17 | director | 2,000 0.0039% | $11.80 | $23,600 | -10.81% | |||
| 2022-11-18 | director | 1,000 0.002% | $12.69 | $12,690 | -0.93% | |||
| 2022-11-09 | director | 2,000 0.004% | $12.75 | $25,500 | +0.08% | |||
| 2022-11-08 | director | 2,000 0.004% | $12.89 | $25,780 | -1.77% | |||
| 2022-11-08 | director | 426 0.0009% | $13.57 | $5,781 | -1.77% | |||
| 2022-11-07 | director | 8,300 0.0163% | $12.69 | $105,327 | -2.15% | |||
| 2022-11-04 | director | 1,700 0.0034% | $12.58 | $21,386 | +1.19% |
Insider Historical Profitability
| Bolton Jeffrey | director | 94144 0.1872% | $7.41 | 13 | 0 | <0.0001% |
| Langham Ronald Leroy JR | EVP Clinical Excel. & Strategy | 57164 0.1137% | $7.41 | 1 | 1 | <0.0001% |
| Hoeflinger Erin | director | 30399 0.0605% | $7.41 | 3 | 0 | <0.0001% |
| Jacobsmeyer Barbara Ann | President and CEO | 238442 0.4742% | $7.41 | 1 | 0 | +3.36% |
| SHAW L EDWARD JR | director | 38989 0.0775% | $7.41 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $93.2M | 15.95 | 8M | -1.17% | -$1.1M | <0.01 | |
| Deerfield Management | $58.22M | 9.96 | 5M | 0% | +$0 | 0.14 | |
| The Vanguard Group | $53.95M | 9.23 | 4.63M | -18.85% | -$12.53M | <0.01 | |
| AREX Capital Management, LP | $28.12M | 4.81 | 2.41M | -0.03% | -$9,424.85 | 31.49 | |
| State Street | $23.2M | 3.97 | 1.99M | -0.82% | -$190,920.20 | <0.01 |